Application of a deep learning algorithm for the diagnosis of HCC
- PMID: 39687602
- PMCID: PMC11648772
- DOI: 10.1016/j.jhepr.2024.101219
Application of a deep learning algorithm for the diagnosis of HCC
Abstract
Background & aims: Hepatocellular carcinoma (HCC) is characterized by a high mortality rate. The Liver Imaging Reporting and Data System (LI-RADS) results in a considerable number of indeterminate observations, rendering an accurate diagnosis difficult.
Methods: We developed four deep learning models for diagnosing HCC on computed tomography (CT) via a training-validation-testing approach. Thin-slice triphasic CT liver images and relevant clinical information were collected and processed for deep learning. HCC was diagnosed and verified via a 12-month clinical composite reference standard. CT observations among at-risk patients were annotated using LI-RADS. Diagnostic performance was assessed by internal validation and independent external testing. We conducted sensitivity analyses of different subgroups, deep learning explainability evaluation, and misclassification analysis.
Results: From 2,832 patients and 4,305 CT observations, the best-performing model was Spatio-Temporal 3D Convolution Network (ST3DCN), achieving area under receiver-operating-characteristic curves (AUCs) of 0.919 (95% CI, 0.903-0.935) and 0.901 (95% CI, 0.879-0.924) at the observation (n = 1,077) and patient (n = 685) levels, respectively during internal validation, compared with 0.839 (95% CI, 0.814-0.864) and 0.822 (95% CI, 0.790-0.853), respectively for standard of care radiological interpretation. The negative predictive values of ST3DCN were 0.966 (95% CI, 0.954-0.979) and 0.951 (95% CI, 0.931-0.971), respectively. The observation-level AUCs among at-risk patients, 2-5-cm observations, and singular portovenous phase analysis of ST3DCN were 0.899 (95% CI, 0.874-0.924), 0.872 (95% CI, 0.838-0.909) and 0.912 (95% CI, 0.895-0.929), respectively. In external testing (551/717 patients/observations), the AUC of ST3DCN was 0.901 (95% CI, 0.877-0.924), which was non-inferior to radiological interpretation (AUC 0.900; 95% CI, 0.877--923).
Conclusions: ST3DCN achieved strong, robust performance for accurate HCC diagnosis on CT. Thus, deep learning can expedite and improve the process of diagnosing HCC.
Impact and implications: The clinical applicability of deep learning in HCC diagnosis is potentially huge, especially considering the expected increase in the incidence and mortality of HCC worldwide. Early diagnosis through deep learning can lead to earlier definitive management, particularly for at-risk patients. The model can be broadly deployed for patients undergoing a triphasic contrast CT scan of the liver to reduce the currently high mortality rate of HCC.
Keywords: AI; CT; HCC; Imaging; LIRADS; Liver cancer.
© 2024 The Author(s).
Conflict of interest statement
W-KS received speaker’s fees from AstraZeneca, is an advisory board member and received speaker’s fees from Abbott, received research funding from Pfizer, Alexion Pharmaceuticals, Ribo Life Sciences and Boehringer Ingelheim, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. M-FY is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, and Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation, and Sysmex Corporation. The remaining authors have no conflict of interests. Please refer to the accompanying ICMJE disclosure forms for further details.
Figures





References
-
- Ferlay J., Erivik M., Lam F., et al. International Agency for Research on Cancer; Lyon, France: 2022. Global cancer observatory: cancer today.https://gco.iarc.fr/today
-
- Wang J.H., Wang C.C., Hung C.H., et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412–418. - PubMed
LinkOut - more resources
Full Text Sources